Want to see HK:9955 full AI Analyst Report?
ClouDr Group Limited (9955) AI Stock Analysis
ClouDr Group Limited
(HKEX:9955)
The score is primarily constrained by severe profitability and cash-flow weaknesses, including declining revenue, substantial net losses, negative ROE, and negative free cash flow. Weak technical momentum and the negative P/E ratio provide additional downside signals, although improved equity, gross margins, and operating cash flow offer limited stabilization evidence.
ClouDr Group Limited (9955) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 258.29M
- Dividend Yield
- ―
- Average Volume (3M)
- 208.50K
- Price to Earnings (P/E)
- -0.5
- Beta (1Y)
- 0.94
- Revenue Growth
- -37.76%
- EPS Growth
- 60.28%
- Country
- Hong Kong
- Employees
- 776
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Distribution
ClouDr Group Limited Business Overview & Revenue Model
Company Description
ClouDr Group Limited operates as an investment holding company, providing a diverse range of services within the healthcare sector. The firm supplies hospitals and pharmacies with crucial medical products, including devices like blood glucose meters...
How the Company Makes Money
ClouDr Group Limited primarily makes money by selling healthcare products to end customers through its retail channels. Its main revenue stream is retail sales generated in physical pharmacies and via online channels, with product categories generall...
ClouDr Group Limited Financial Statement Overview
Summary
Financial health remains distressed despite positive equity, improved gross margins, and a return to positive operating cash flow. Sharp revenue decline, a -57% net profit margin, deeply negative ROE, and negative free cash flow constrain the score.
Income Statement
22NegativeBalance Sheet
45NeutralCash Flow
38Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.36B | 1.62B | 3.49B | 3.69B | 2.99B | 1.76B |
| Gross Profit | 737.81M | 775.08M | 861.67M | 909.38M | 792.10M | 570.02M |
| EBITDA | 24.16M | -508.87M | -372.34M | -208.37M | -1.58B | -4.06B |
| Net Income | -404.85M | -924.15M | -516.41M | -323.06M | -1.69B | -4.14B |
Balance Sheet | ||||||
| Total Assets | 1.47B | 1.68B | 2.84B | 2.95B | 2.83B | 2.51B |
| Cash, Cash Equivalents and Short-Term Investments | 442.74M | 449.77M | 532.16M | 595.10M | 723.17M | 1.12B |
| Total Debt | 210.16M | 288.75M | 581.24M | 267.05M | 228.67M | 9.03B |
| Total Liabilities | 1.03B | 1.20B | 1.41B | 1.18B | 953.05M | 9.66B |
| Stockholders Equity | 511.00M | 548.79M | 1.45B | 1.83B | 1.85B | -7.14B |
Cash Flow | ||||||
| Free Cash Flow | 13.49M | -65.22M | -225.19M | -263.46M | -809.87M | -755.02M |
| Operating Cash Flow | 48.28M | 82.38M | -148.39M | -140.43M | -642.63M | -666.33M |
| Investing Cash Flow | -98.93M | 9.33M | 66.87M | -38.34M | -744.94M | -155.50M |
| Financing Cash Flow | -59.78M | -32.72M | 147.99M | 171.81M | 503.55M | 1.02B |
ClouDr Group Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:9955, the sentiment is Negative. The current price of 0.40 is below the 20-day moving average (MA) of 0.44, below the 50-day MA of 0.47, and below the 200-day MA of 0.63, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 33.91 is Neutral, neither overbought nor oversold. The STOCH value of 42.75 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:9955.
ClouDr Group Limited Peers Comparison
Overall Rating
HK:219271Outperform
HK:109965Neutral
HK:228947Neutral
HK:067339Underperform- HK:995538Underperform
HK:193126Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:2192 | 71Outperform | HKD 4.67B | 11.61 | 7.05% | 4.98% | 6.47% | 8.10% |
| HK:1099 | 65Neutral | HKD 50.52B | 6.09 | 8.33% | 4.88% | 2.78% | 7.71% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:2289 | 47Neutral | HKD 592.92M | 10.81 | 7.70% | 6.26% | 14.25% | 0.83% |
| HK:0673 | 39Underperform | HKD 360.66M | -5.29 | -273.18% | ― | 5.52% | 56.54% |
| HK:9955 | 38Underperform | HKD 257.37M | -0.52 | -76.42% | ― | -37.76% | 60.28% |
| HK:1931 | 26Underperform | HKD 575.63M | -6.45 | -2.60% | ― | -2.55% | -145.60% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:9955 | ClouDr Group Limited | 0.40 | -0.76 | -65.52% | |
| HK:0673 | China Health Group | 0.26 | -0.42 | -61.76% | |
| HK:1099 | Sinopharm Group Co Class H | 16.19 | -2.28 | -12.34% | |
| HK:1931 | IVD Medical Holding Limited | 0.35 | -5.62 | -94.05% | |
| HK:2192 | Medlive Technology Co., Ltd. | 6.30 | -3.44 | -35.33% | |
| HK:2289 | Charmacy Pharmaceutical Co., Ltd. Class H | 5.49 | -0.13 | -2.26% |
ClouDr Group Limited Corporate Events
ClouDr Narrows Losses But Revenue Falls Nearly 30% in First-Half 2026
ClouDr Group Limited reported a sharp year-on-year revenue decline for the six months ended June 30, 2026, with total revenue falling 29.5% to RMB629.2 million as both in-hospital and out-of-hospital solutions contracted across subscription, value-ad...
ClouDr Group Sets Board Meeting to Approve 2026 Interim Results
ClouDr Group Limited has scheduled a board meeting for August 27, 2026, to review and approve the interim financial results for the six months ended June 30, 2026. The meeting will also address the publication of these results and any other business,...
ClouDr Group Signals Sharp Narrowing of Interim Loss on AI-Driven Turnaround
ClouDr Group Limited reported that its consolidated net loss for the six months ended June 30, 2026 is expected to narrow sharply to between RMB60 million and RMB10 million, from RMB642.9 million a year earlier. The board attributed this improvement...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 22, 2026